Home/Pipeline/CLS12311

CLS12311

Multiple Sclerosis

Phase 2Active

Key Facts

Indication

Multiple Sclerosis

Phase

Phase 2

Status

Active

Company

Cellerys

About Cellerys

Cellerys, a 2019 spin-off from the University of Zurich, is pioneering antigen-specific tolerance induction therapies for autoimmune diseases, starting with multiple sclerosis. Its innovative approach uses autologous red blood cells coupled with peptides to re-establish immune tolerance, differentiating it from non-specific immunosuppressive drugs. The company has successfully completed a Phase Ib trial (RED4MS) with Novartis and is preparing for a Phase IIa study, backed by a leadership team with deep expertise in neuroimmunology and MS research.

View full company profile

Therapeutic Areas

Multiple Sclerosis Autoimmune Diseases

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active
Evobrutinib	EMD Serono	Phase 3	Active